Cogent Biosciences, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $312.0M | $98.2M | $53.2M | $139.9M | $219.7M | $242.2M | $37.4M | $55.7M |
| Accounts Receivable | — | — | — | — | — | — | $2.0M | $1.7M |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $910.4M | $296.5M | $270.8M | $265.0M | $222.6M | $244.9M | $40.6M | $81.0M |
| Property, Plant & Equipment | $5.5M | $6.5M | $8.3M | $7.8M | $1.7M | $134.0K | $1.9M | $3.3M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $937.6M | $327.9M | $313.4M | $300.8M | $232.1M | $250.9M | $49.4M | $85.9M |
| Liabilities | ||||||||
| Accounts Payable | $9.5M | $12.0M | $10.7M | $5.8M | $3.5M | $732.0K | $3.2M | $1.5M |
| Total Current Liabilities | $64.0M | $55.7M | $38.2M | $26.8M | $17.1M | $13.1M | $13.2M | $24.9M |
| Long-Term Debt | $222.9M | — | — | — | — | — | — | — |
| Total Liabilities | $301.2M | $71.6M | $55.6M | $45.1M | $17.9M | $16.2M | $17.7M | $25.7M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.19B | $-859.5M | $-603.6M | $-411.2M | $-271.0M | $-198.7M | $-123.9M | $-92.1M |
| Total Stockholders' Equity | $636.4M | $256.3M | $257.8M | $255.7M | $214.2M | $234.7M | $31.8M | $60.2M |